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Abstract
Moderate or severe pain are important sources of complications as well as morbidity and 
mortality in the postoperative period after surgical procedures. Patient‐controlled analge‐
sia (PCA) is an effective strategy for postoperative analgesia, since it may provide suitable 
analgesic dose just after system activation, with reduced periods of pain and an increase in 
patients’ satisfaction. Although intravenous and epidural routes are the typical approaches 
used for PCA, regional patient‐controlled analgesia has been shown to be an effective alter‐
native providing a higher standard of analgesia with lower incidence of adverse effects. 
New devices and routes of PCA administration (transdermal, sublingual, inhalation, and 
oral routes) have shown to be promising alternatives in clinical studies. Nowadays, there is 
still no consensus regarding which is the best route or drug used since clinical efficacy/safety 
depends on the complex comprehension of the drugs pharmacokinetic profile through dif‐
ferent routes of administration. Additionally, pharmacoeconomic studies are needed to 
evaluate the cost‐effectiveness of these approaches.
Keywords: patient‐controlled analgesia, opioids, acute pain, analgesic medication, 
morphine
1. Introduction
The International Association for Study of Pain defines pain as an unpleasant experience, with 
or without tissue damage, which can be related to individual memories, life expectations and 
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emotions [1]. The painful experience involves interpretation of biological aspects of pain and 
its interaction with social and cultural characteristics [2].
In surgical procedures, moderate to severe pain can be observed in up to 40% of cases [3], 
representing an important source of complications as well as morbidity and mortality in 
the postoperative period [4]. Postoperative pain can limit mobility and respiratory function, 
increasing the incidence of atelectasis, pneumonia and thromboembolic events [5, 6].
Moreover, the lack of adequate pain control in acute situations can lead to chronic pain, with 
deleterious effects for the patient and health‐related quality of life [7]. Despite these findings, 
between 50% to 75% of those submitted to major surgery do not receive enough analgesic 
medication, increasing the risk of complications and length of stay and costs for the health 
system [8].
Morphine was isolated by a German pharmacist Friedrich Wilhem Sertürner in 1806 and, 
after that, opioids have become widely used in clinical practice for pain control. Later in 1844, 
parenteral administration of morphine has started after the introduction of glass syringe [2].
In 1963, Roe demonstrated that administration of small doses of intravenous morphine 
allowed a better pain control compared to intramuscular injections [9]. Sechzer, in 1968, 
was the first to evaluate the quality of analgesia after administration of small doses of 
opioids per patient request, performing the first patient‐controlled analgesia (PCA). Due 
to complex logistic to meet the requests of many patients, which would require numerous 
nursing staff, Sechzer and other doctors began to develop equipment prototypes for anal‐
gesic administration with reduced costs. The first PCA pump available for marketing was 
named “Cardiff Palliator” and it was developed in the Welsh National School of Medicine 
in 1973 [10, 11].
Since then, several drugs and routes of administration have been used in PCA, with differences 
in analgesic efficacy, tolerability profile, adverse effects, and procedure‐related complications 
as well as patient satisfaction [12].
2. PCA: principles and pharmacological aspects
The principle of intravenous PCA was first described by Austin et al. in 1980, after he admin‐
istrated small increasing doses of meperidine and measured the plasma levels, demonstrating 
the dose‐related analgesic effect in patients [13].
Despite being associated with the idea of pump with intravenous opioids, there are several 
routes of administration, drugs, and equipment that can be used in this mode of analgesia. 
It is essential that, for the PCA recommendation, individual pain pattern and intensity be 
considered.
The patients must be previously and duly enlightened on the technical procedure and their 
consent should be obtained. As desirable characteristics of PCA, we can highlight the ade‐
quate pain relief according to individual requirements, the tolerance and safety profile of 
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drugs administered, the high level of patients’ satisfaction and minimal complications related 
to technological aspects [12].
In order to understand the effectiveness of PCA, we need to understand the concept of “minimal 
effective analgesic concentration (MEAC).” The MEAC is defined as the smallest concentration 
at which the pain is relieved [13].
Considering the existence of individuals’ variability, the MEAC cannot be determined from 
the plasma levels of opioids. It is known that the plasma concentration is a function related 
to the dose, dosage intervals, gender and age of the patient. It can be calculated based on 
pharmacokinetic concepts such as volume of distribution and distribution and elimination 
rates. However, in clinical situations, the plasma levels are not able to predict the pattern of 
analgesic response [14]. Tamsen et al. showed that the MEAC has a direct correlation with 
preoperative concentrations of endogenous opioids and substance P in the cerebral spinal 
fluid. Obviously, the achievement of these measurements is restricted in clinical practice [15].
For the PCA effectiveness, the MEAC should be achieved by titration, which means that the 
drug is administered as a bolus of small doses until the establishment of an adequate analgesia 
pattern is obtained. Considering the acute postoperative pain, this can be done in the post‐
anesthetic recovery room, before patient discharge. From this reference dose, the equipment 
is regulated in order to maintain the plasma concentration of analgesic levels of MEAC or 
slightly above it, looking for adequate pain control with minimal adverse effects. The goal of 
this approach is to prevent the occurrence of sharp peaks and troughs in plasma concentra‐
tions in a standard that seeks the lowest level of oscillation of concentrations, ideally as close 
to a continuous infusion [16].
Regardless of the route or administered drug, the two main types of PCA are: the demand 
dosing (the fixed dose which is self‐administered intermittently) and continuous infusion 
associated with demand dosing (the constant‐rate fixed background infusion is supplemented 
by patient demand dosing), whereas the principles of a fixed infusion administration as well 
as principles of variation of the infusion rates managed by a period of time are considered [17].
Some basic principles and technical parameters are common to several modalities. They are 
initial loading dose, demand dose, interval lockout, and background infusion rate.
The initial dose usually is not administered by the patient, since the goal of first administration 
is to promote adequate pain control or prevent the early pain manifestation. This approach 
allows the establishment of the demand dose, also called PCA dose or bolus dose, which will 
be administered by the patient when he shoots the demand button.
The lockout interval is a set period in which the equipment does not perform a new infusion of 
demand. During the interval lockout, if the patient triggers the button, he/she will not receive 
the medication. Normally, the equipment has a sound signal connected to the drive, regard‐
less of the infusion, so that the patient does not know whether his/her requests were effective. 
The lockout interval has the primary function of security by preventing the administration 
of an overdose of analgesic drugs. The background infusion rate is a given infusion rate in a 
continuous manner, independent of the patient's wish (also called continuous infusion). The 
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1‐h and/or 4‐h limits, depending on the equipment configuration, it has the function to limit 
the total cumulative dose in the period of 1 or 4 h in order to reduce the adverse effects and 
ensure the patient safety [11, 18].
Considering the advances in the development of drug delivery systems, the use of infusion 
pumps for patient‐controlled analgesia (PCA) and analgesia epidural catheter with opioids 
are considered the most powerful strategies to control of postoperative pain. However, there 
are doubts about the advantages and limitations of these different forms of PCA.
The basal opioid administration doses may be administered concurrently with the adminis‐
tration of opioids by PCA techniques. However, the basal administration increases the risk 
of respiratory depression without providing necessarily an additional analgesia pattern [19].
PCA different modalities can minimize the occurrence of gaps in analgesic administration, 
supplying analgesic dosage immediately after the system activation, providing more uniform 
analgesia and eliminating painful waiting periods between the patient's request and drug 
administration.
3. PCA modalities
Electronic PCA pumps have several models in the market, including small portable devices 
nowadays. Since the first commercially available PCA pump (“Cardiff Palliator”), PCA 
devices have evolved enormously in technological sophistication, ease of use, flexibility and 
portability.
3.1. Intravenous PCA (IV‐PCA)
Currently, IV‐PCA is one of the most used techniques for acute pain control. Its use is suit‐
able for virtually any patient undergoing surgery that are cursed with postoperative pain 
of moderate or severe intensity [18]. Many studies have demonstrated the efficacy, safety, 
and patient satisfaction with PCA intravenously. A meta‐analysis involving 115 randomized 
clinical trials demonstrated that this technique provides greater efficacy when compared to 
intramuscular administration of analgesics [20]. Another study showed that, among patients 
who received IV‐PCA, 36% experienced moderate to severe pain in the first 24 h after surgery 
when compared to 67% of important painful experience among patients who received intra‐
muscular opioids [21]. Moreover, it was verified that the IV‐PCA is associated with a higher 
rate of patient satisfaction [22].
Despite the possibility that IV‐PCA may be combined to a basal opioids infusion, it was 
shown that the incidence of respiratory depression with IV‐PCA was much smaller (0.19% 
versus 0.29%) when compared to the combination of this technique with systemic infusion of 
opioids (1.09–3% versus 8%) [23].
IV‐PCA is associated with potential complications inherent in the technique, which are opera‐
tor‐dependent. Errors may occur in the drug administration, usually by programming failures 
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on infusion pump [24] and they may result in inadequate pain control, heavy sedation, respira‐
tory depression, and, eventually, death of the patient [25]. Currently, many infusion pumps 
feature smart devices that are equipped with an integrated software library on dosing regimens 
of different drugs, thus avoiding underdosing or overdosing. In these models, the smart bombs 
are programmed to stop operation or to alert clinicians when doses exceed the limits [26].
However, serious errors can still occur even with smart bombs. According to the Food and 
Drug Administration (FDA), 56,000 adverse events with these smart bombs during the period 
2005–2009 have been reported [27].
Several complications may be observed from the IV‐PCA, such as clogging or dislodgement 
of catheters, intervals between the administrations of opiates for maintenance of analgesic 
effect [28]. Still, this technique implies in risk for adverse effects related to opioids [29].
Furthermore, IV‐PCA limits mobility and it reduces the comfort of the patient who is con‐
nected to the infusion pump, which can be minimized by using more modern compact equip‐
ment. Zafar et al. [30] reported that about 21% of patients who received IV‐PCA complained 
of reduced mobility. It is worth noting, finally, the economic aspect, as a limitation of the 
technique, as well as the need of equipment (infusion pump) and the discarding of remaining 
solutions after the PCA use, causing unnecessary costs for health services [12, 30].
The major drugs used in this system are the opioid analgesics, such as morphine, hydromor‐
phone, fentanyl, sufentanil and tramadol [31]. Meperidine is no longer considered a valid 
option for PCA as its toxic metabolite may be accumulated, especially in patients with abnor‐
mal kidney function [32]. Therefore, meperidine has not been recommended for acute pain [33].
3.1.1. Morphine
Morphine is the most common opioid used for IV‐PCA and it is considered the gold standard 
for this procedure. Although many studies have demonstrated its clinical safety, adverse effects 
such as nausea, vomiting, itching, urinary retention, sedation  and respiratory depression may 
occur. Its active metabolite morphine‐6‐glucuronide (M6G) have analgesic action but presents 
risk of adverse effects. As the M6G has renal elimination, the use of morphine should be done 
with caution in patients with impaired renal function and the elderly [34, 35]. The low thera‐
peutic index of morphine in IV‐PCA was shown in preclinical models, indicating that morphine 
cannot be the best option for all patients for pain relief in the postoperative period [31].
The usual morphine dose and the recommended parameters are: demand dose: 1–2 mg; lock‐
out period: 6–10 min; continuous basal infusion dose: 0–2 mg/h [11].
3.1.2. Hydromorphone
Hydromorphone has been used in patients with impaired renal function or with a history of 
allergy to morphine. It is mainly metabolized by the liver and it is, approximately, five times 
more potent than morphine. Clinical effects of hydromorphone are dose‐dependent and its 
adverse event profile is morphine‐like [11, 36]. A systematic review of adverse events associated 
with the postoperatory use of six different opioids (buprenorphine, fentanyl, hydromorphone, 
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meperidine, morphine, and sufentanil) showed that after meperidine (proscribed, 67.9%), the 
opioid with the highest incidence of central nervous system side effects was hydromorphone 
(42.7%). Furthermore, at higher doses, hydromorphone can cause excitation [37].
Due to the similarity between morphine and hydromorphone, errors have been reported in 
programming the IV‐PCA pump. Considering that these agents have significant differences 
in their clinical potency, inadvertent hydromorphone administration can result in serious 
complications [38].
Doses and recommended parameters are: demand dose: 0.2–0.4 mg; lockout period: 6–10 min; 
continuous basal infusion dose: 0–0.4 mg/h [11].
3.1.3. Fentanyl
Fentanyl is 80–100 times more potent than morphine and it may cause less respiratory depres‐
sion when compared with morphine. It has no active metabolites, and it has a wider therapeutic 
index than morphine in preclinical models [39].
In a retrospective cohort study of 8955 patients who received one of the three opioids for post‐
operative pain (morphine, fentanyl or meperidine), the incidence of respiratory depression 
was 0.6% in the group of patients who received fentanyl, compared to 2.8% among patients 
who received morphine [40]. Although apparently it may be associated with smaller risk of 
respiratory depression when compared to morphine, fentanyl can be associated with more 
device programming errors, since this drug is dosed in micrograms [40, 41].
Because of its high lipid solubility, fentanyl has a pharmacokinetic profile characterized by a 
rapid onset and short action. Therefore, some patients may need doses too frequently or require 
a basal infusion rate, which greatly increases the risk of respiratory depression. Due to its high 
volume of distribution, prolonged administration may result in a significant increase in drug 
half‐life, with consequent raise in the incidence of adverse effects [42]. Given these pharmaco‐
kinetic characteristics, there are complaint reports of patients after fentanyl administration in 
IV‐PCA [43].
Doses and recommended parameters: demand dose: 20–50 µg; lockout: 5–10 min; Basal 
continuous: 0–60 µg/h [11].
3.1.4. Sufentanil
Sufentanil is a fentanyl analog, being about 5–10 times more potent than Fentanyl itself. It rep‐
resents the opioid with greater therapeutic index (25,000) used for postoperative pain in pre‐
clinical studies [39]. The high therapeutic index is clinically relevant for evoking a decreased 
risk of incidence of respiratory depression compared to morphine, fentanyl, and alfentanil [44]. 
In a randomized clinical trial with 30 volunteers, it was noted that sufentanil provided more 
effective analgesia and less respiratory depression when compared with fentanyl [44].
Sufentanil is highly lipophilic (twice more lipophilic than fentanyl) and it provides rapid onset 
of action and shorter effect duration when administered intravenously to PCA, justifying its 
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rare use in this route. However, unlike fentanyl, its half‐life of elimination does not increase 
with infusion time and it shows paradoxical increase in their concentration during the elimina‐
tion phase [39]. A randomized clinical trial that compared plasma levels of sufentanil and fen‐
tanyl in 41 patients undergoing coronary artery bypass surgery, demonstrated the occurrence 
of peak plasma concentration (increase of 29–49%) from 4 to 15 h after administration bolus of 
fentanyl. On the other hand, only one patient had sufentanil treated with this paradoxical effect 
(43% increase). This peak in plasma concentration explains the occurrence of late respiratory 
depression in patients treated with fentanyl [45]. Therefore, considering their high therapeu‐
tic index and predictable pharmacokinetic profile, sufentanil represents a promising example 
of opioid that could be used to PCA cases requiring short duration of effect and availability 
intravenously.
The doses and the usual parameters are: demand dose: 4–6 µg; lockout: 5–10 min; continuous 
baseline: 0–8 µg/h [11].
3.1.5. Tramadol
Tramadol acts on opioid receptors with higher affinity for κ receptors than δ and µ receptors. 
It has an active metabolite, mono‐O‐desmethyl (M1), which has analgesic effect. In addition 
to the opioid agonist activity, tramadol analgesia is also promoted by inhibiting the central 
norepinephrine and serotonin reuptake. Tramadol potency compared to morphine is approx‐
imately 0.1. Several studies have shown that tramadol is a safe and an effective option for 
PCA, but with a higher incidence of nausea and vomiting [46, 47]. The recommended doses 
are: demand dose: 10–20 mg; lockout: 6–10 min; continuous baseline: 0–20 mg/h [11].
3.1.6. Oxycodone
Oxycodone is an opioid µ receptor agonist indicated for the treatment of moderate to severe 
pain. Despite being most frequently used orally, in recent years, its intravenous use has 
increased. Its potency is about 1/75 of fentanyl, and in some studies has shown great potency 
up to 1/60 [48, 49].
A randomized clinical trial with 82 patients compared IV‐PCA with oxycodone and fentanyl. 
In this study, oxycodone demonstrated potency of 1/55 of fentanyl for the same levels of anal‐
gesia, being equally safe and the same incidence of adverse effects such as nausea, vomiting 
and sedation [45]. It is a drug with good efficacy and a promising role in the practice of PCA. 
Its use must be made on demand associated with basal infusion. The recommended doses are: 
demand bolus: 1 mg; lockout: 15 min; background infusion rate: 1 mg/h [50].
3.1.7. Other drugs
Other opioids have been less used in IV‐PCA. The alfentanil, probably due to their pharma‐
cokinetic characteristics, did not show good results and a demand dose was not established 
to present a satisfactory analgesia [51]. The remifentanil, because of their ultrashort half‐life, 
does not have a favorable profile for PCA with some indication for analgesia for a short period 
such as during labor [52].
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Other drugs have been used by some authors that are normally associated with morphine. 
Ketamine, which is an agonist of the NMDA receptor, and naloxone, which is an antagonist of 
opioid receptors, have shown conflicting results regarding the safety or quality of analgesia, 
and more studies are needed so that they can get their recommended use [18].
3.2. Epidural PCA
Epidural patient‐controlled analgesia (EPCA) is the second most significant method used 
and studied within the PCA approach. Its use is mainly for control of acute postoperative 
pain, commonly in patients undergoing orthopedic, abdominal and thoracic surgery [12]. 
EPCA allows the use of opioids, local anesthetics, or a combination of both. Opioids epidural 
administered provide greater analgesic potency when compared to equivalent doses of opioid 
administered intravenously [53].
Although both opioids and local anesthetics represent feasible options, local anesthetics are the 
most appropriate strategies for patients sensitive to the opioids adverse effects, even though it 
is associated with a higher incidence of hypotension, motor block and urinary retention com‐
pared with the use of opioids [53]. Similarly to the PCA intravenous technique, EPCA allows 
patients to administer the medication in accordance with analgesic requirements. There is large 
evidence indicating that the EPCA represents a safe and effective method [46, 54]. A meta‐anal‐
ysis concluded that, regardless of the drug chosen, epidural provides a better analgesia pattern 
when compared to intravenous PCA technique [55].
In a population‐based study of 2276 surgical patients, Kim et al. [56] discloses that ropivacaine 
with fentanyl was able to provide good quality analgesia for up to 48 h after the several surgical 
procedures, with limited side effects [56].
Unlike IV‐PCA, the use of continuous infusion, coupled with the demand dose, have shown 
excellent results with minimal complications. Small doses of local anesthetics of long action 
combined with low doses of opioids (i.e., fentanyl or sufentanil) with continuous infusion 
rate associated with increments bolus may be combined [57, 58]. The following concentrations 
are recommended: bupivacaine: 0.05–0.125%; levobupivacaine: 0.05–0.125%; ropivacaine: 
0.1–0.2%. Additionally, the following doses are recommended: demand dose: 2–4 ml; lockout: 
10–20 min; continuous basal infusion: 4–10 ml/h [11].
Despite many advantages, EPCA also has limitations, especially considering the complexity 
of the procedure and technical staff training. In addition, there are reports of catheter migra‐
tion which may lead to failure in the procedure in 17% of cases. It has been suggested that this 
technique has great effectiveness but it should be used with caution considering individual 
factors, in order to ensure patient safety [56].
3.3. Patient‐controlled regional analgesia
There are several techniques that use catheters for the purpose of providing postoperative 
analgesia with little or no opioid use. In this model of patient‐controlled regional analgesia, 
local anesthetics (ropivacaine, bupivacaine or levobupivacaine) are normally administered 
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through a catheter located in perineural site, intraarticular region or surgical incision site. 
Eventually, a combination of local anesthetics and opioids can be administered by the infu‐
sion pump [12].
Several studies have addressed the effectiveness of this method for postoperative analgesia [59]. 
Vintar et al. [60] noted that about 80% of patients who received bupivacaine and ropivacaine at 
the incision site were satisfied with the outcome of the procedure and said they would use this 
treatment again.
Studies emphasizing the intraarticular administration of opioids and/or local anesthetics are 
rare. Vintar et al. [60], in a controlled clinical trial, describes that the group which received 
the combination of ropivacaine/morphine/ketorolac required less use of rescue analgesics in 
relation to other groups.
It is estimated that, during orthopedic surgery, drug administration by intraarticular can pro‐
vide 12–15 h of analgesia [61]. In this context, the most efficient strategy would be the infusion 
of local anesthetics via epidural. Additionally, the brachial plexus, lumbar plexus and femoral 
nerve and sciatic nerve are examples of sites for drugs infusion. In a clinical trial, the PCRA 
ropivacaine 0.2% in the brachial plexus region was effective in shoulder orthopedic surgery 
regarding pain intensity, opioids’ use as rescue medication, and less sleep disorders [61].
In a multicenter study involving orthopedic surgeries, the perineural ropivacaine adminis‐
tration by continuous infusion or PCRA was compared to intravenous morphine. Patients 
receiving morphine showed higher levels of postoperative pain and required higher con‐
sumption of analgesic as rescue medication, significantly increasing the side effects such as 
nausea, vomiting, dizziness and sleep disturbances [62].
3.4. Other modalities of patient‐controlled analgesia
3.4.1. Transdermal
The iontophoretic fentanyl system (IONSYS; Ortho‐McNeil, Raritan, NJ, USA) is a prepro‐
grammed noninvasive method of PCA, which does not require venous access for drug admin‐
istration. By adhesively secured to the outside of the arm or chest of the patient, fentanyl is 
transferred iontophoretically through intact skin. The system allows the transdermal admin‐
istration of the drug for 10 min and a 10 min lockout interval between administrations [39].
However, the fentanyl dose administered over time is not constant. Whereas the target dose 
for the desired effect of fentanyl is 40 µg, it is estimated that the average dose is 16 µg after 
the initial application. Therefore, it would take a long period of time until the optimal dose is 
reached. Many patients do not receive adequate analgesia for up to 10 h after the start of the 
application [39].
Although clinical studies have suggested that the use of transdermal fentanyl could show simi‐
lar efficacy to morphine in PCA intravenously in relation to the overall control of pain [12], there 
was a need for additional analgesia in 40% of patients involved in the first 3 h of treatment. 
Moreover, there were local side effects such as skin redness in about 60% of cases. This system 
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was not marketed in the U.S. and it was withdrawn from the European market by the manufac‐
turer due to a manufacturing error in some units [38].
3.4.2. Sublingual
A new sublingual administration system using sufentanil (AcelRx Pharmaceuticals, Redwood 
City, CA, USA) is designed as a microtablet coupled to a preprogrammed portable device with 
locking features and radio frequency identification to enable the characterization of a single 
user. Although intravenous sufentanil present a short half‐life context‐dependent due to its 
rapid redistribution, pharmacokinetic studies in healthy subjects showed that after sublingual 
administration, sufentanil has adequate profile for the postoperative analgesia [39].
Sufentanil NanoTabs® shows high bioavailability and plasma half‐life and it is safer than 
the administration of the drug intravenously to avoid the need for frequent administrations 
of the lipophilic opioids commonly used for this procedure. Several clinical trials have dem‐
onstrated its efficacy in pain relief in different types of orthopedic and abdominal surgery, 
having been described few side effects to this method [38].
3.4.3. Inhalation
Several products using the inhalation of PCA to opioid administration are described in the 
literature. Thipphawong et al. [63] tested a morphine inhalation system (System AERx Pain 
Management; Aradigma Corporation, Hayward, CA, USA), which had desirable character‐
istics of a drug for PCA (possibility of multiple dosing with lock time between them and 
observed similar efficacy to morphine IV‐PCA).
Similarly, fentanyl (AeroLEF, YM Biosciences, Mississauga, ON, Canada) also had proven to 
control postoperative pain following orthopedic surgery. However, further studies are needed 
to confirm the effectiveness of opioids in this route, especially clinical trials phase III and IV.
3.4.4. Intranasal
The intranasal opioid administration is possible, since the nasal mucosa has an extensive vas‐
cularization, providing rapid drug absorption and distribution [12].
The presentation of intranasal morphine (Rylomine®, Javelin Pharmaceuticals Inc., 
Cambridge, MA, USA) was effective for the control of postoperative pain in orthopedic sur‐
gery [64]. However, the single dose after a nasal administration does not have the desirable 
safety features of PCA models, such as the possibility of multiple dosages and lock scheduled 
time between applications. Other opioids have been tested for intranasal administration but 
similar to morphine, these devices also did not have the desirable features of a PCA device. In 
this context, Toussaint et al. [65] noted that intranasal fentanyl administration showed similar 
efficacy compared to IV‐PCA fentanyl. Intranasal sufentanil was also successfully used both 
in adults and pediatric patients [64].
However, this route may have local adverse effects: nasal irritation, nasal congestion, upper 
respiratory tract infections, sinusitis, rhinitis, pharyngitis, or epistaxis, which may be a limitation 
of its clinical use [66].
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3.4.5. Oral
Oral PCA device (Avancen, Mount Pleasant, SC, USA) is a drug unit coupled to a bracelet 
programmed to keep out of the drug for a predetermined time interval. After this lockout 
period, a green light indicates the possibility of new management. The equipment is compact 
and allows the patient to make the registration of pain on a scale of 0–10, providing feedback 
to the health team.
In a study of this device with hydromorphone administration, oxycodone and morphine, it 
was reported better control of pain in 95% of patients who used these devices when compared 
to the control group. Furthermore, it highlighted the ease of programming of this device by 
the health team [38].
Although this oral device for PCA is a good alternative, there are few studies regarding its 
safety. It is noteworthy of some shortcomings: lack of clinical efficacy in cases of moderate to 
severe pain, management failure in patients in whom oral administration is not available and 
uncertain absorption in the immediate postoperative period.
4. Conclusion
Patient‐controlled analgesia (PCA) is a great option for acute pain control. Several advantages 
of this technique can be highlighted, such as higher analgesic standard with patient's satisfac‐
tion, and also minor side effects. However, there is still no consensus regarding which is the 
best route or drug used since clinical efficacy/safety depends on the complex comprehension 
of the pharmacokinetic drugs profile through different routes of administration. Additionally, 
pharmacoeconomic studies are needed to evaluate the cost‐effectiveness of these approaches.
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